🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

11 recruiting trials

for Merkel Cell Carcinoma, Stage I

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors NCT07006727Phase 18 sites📍 Iowa City📍 Boston📍 Royal Oak Novartis Pharmaceuticals · Tests: 225Ac-ETN029, 111In-ETN029 A Study of CRD3874-SI in People With Solid Tumors NCT06021626Phase 17 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: CRD3874 A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer NCT05859074Phase 17 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: MQ719, Pembrolizumab MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors NCT05076760Phase 12 sites📍 Tampa📍 Durham Memgen, Inc. · Tests: MEM-288 Intratumoral Injection, Nivolumab, Docetaxel Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors NCT06814496Phase 1, Phase 23 sites📍 Gilbert📍 Tucson📍 Seattle University of Arizona · Tests: Tarlatamab, Concurrent Radiation Therapy, Sequential Radiation therapy Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab NCT07387198Phase 214 sites📍 Heidelberg📍 Mannheim📍 Tübingen Institut für Klinische Krebsforschung IKF GmbH at Krankenha… · Tests: Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for 2 cycles, Placebo NaCl 0.9% solution i.v. on day 1 of every … Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma NCT06151236Phase 21 site📍 Wollstonecraft Melanoma Institute Australia · Tests: Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma NCT04975152Phase 11 site📍 Tampa H. Lee Moffitt Cancer Center and Research Institute · Tests: Cemiplimab-Rwlc Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors NCT05269381Phase 1, Phase 21 site📍 Jacksonville Mayo Clinic · Tests: Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab, Sargramostim, Biospecimen Collection A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21) NCT07302347Phase 1, Phase 27 sites📍 Nagoya📍 Nagoya📍 Sapporo Merck Sharp & Dohme LLC · Tests: Pembrolizumab A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors NCT07115043Phase 1, Phase 213 sites📍 Grand Rapids📍 St Louis📍 Pittsburgh AstraZeneca · Tests: AZD6750, rilvegostomig
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy